This month, world leaders will gather at the UN General Assembly to address the looming threat of antimicrobial resistance (AMR). They will discuss antimicrobial access, governance, coordination, and many other critical aspects of the fight against AMR.
Yet there’s one critical component to any successful outcome that is overlooked and underfunded: the dwindling antimicrobial research and development field.